Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00054496
Status:
UNKNOWN
Last Update Posted:
2014-01-10
First Post:
2003-02-05
Brief Title:
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Sponsor:
The Cleveland Clinic
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study Trial Of Tarceva In Patients With RecurrentProgressive Glioblastoma Multiforme
Status:
UNKNOWN
Status Verified Date:
2006-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
PURPOSE Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme
PURPOSE Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme
Detailed Description:
OBJECTIVES
Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib
Determine the progression-free and overall survival of patients treated with this drug
OUTLINE Patients receive oral erlotinib daily Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed for survival
PROJECTED ACCRUAL A total of 73 patients will be accrued for this study
Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib
Determine the progression-free and overall survival of patients treated with this drug
OUTLINE Patients receive oral erlotinib daily Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed for survival
PROJECTED ACCRUAL A total of 73 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CCF-IRB-5478 | None | None | None |